A new Treg play­er emerges with $46M and back­ing from Take­da

In re­cent years, the cho­rus of biotechs and Big Phar­ma back­ers tar­get­ing reg­u­la­to­ry T cells — al­so known as “Tregs” — for can­cer and au­toim­mune dis­eases has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER